- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| RESPIRERX Aktie jetzt für 0€ handeln | |||||
| 20.11. | RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties | 105 | GlobeNewswire (Europe) | Glen Rock, N.J., Nov. 20, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (RespireRx or the Company), and its subsidiaries, EndeavourRx LLC (EndeavourRx) and ResolutionRx Ltd (ResolutionRx)... ► Artikel lesen | |
| 19.11. | RespireRx Pharmaceuticals Inc. Announces NIH/NINDS Grant Award and Amended and Restated Patent License Agreement | 157 | GlobeNewswire (Europe) | Glen Rock, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and revolutionary treatments... ► Artikel lesen | |
| 18.11. | RespireRx Pharmaceuticals Inc. Announces Commencement of Rule 506(c) Private Placement | 2 | GlobeNewswire (USA) | ||
| 18.11. | RespireRx Pharmaceuticals Inc. Announces SEC Order Making Findings and Revoking Registration of Securities and Future Plans with respect to its Common Stock | 338 | GlobeNewswire (Europe) | Glen Rock, N.J., Nov. 18, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. ("RespireRx", "RSPI", "Respondent" or the "Company"), a leader in the discovery and development of innovative and... ► Artikel lesen | |
| 14.11. | RespireRx Pharmaceuticals Inc. - REVOKED, Commission order revoking Exchange Act registration [Section 12(j)] | 1 | SEC Filings |
5 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DIGICANN VENTURES | 0,004 | +600,00 % | XFRA VY3: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 66,12 | -0,90 % | Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS) | Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that TRYNGOLZA® (olezarsen) has been approved in the European Union (EU) as an adjunct to diet in adult patients for the treatment... ► Artikel lesen | |
| SINOPHARM | 2,129 | -1,34 % | Sinopharm Group-Aktie heute gut behauptet: Aktienwert steigt (2,08 €) | Der Anteilsschein der Sinopharm Group notiert heute ein wenig fester. Zuletzt zahlten Investoren für das Wertpapier 2,08 Euro. Jahreschart der Sinopharm Group Ltd-Aktie, Stand 11.09.2025 Freuen können... ► Artikel lesen | |
| INDIVA | 0,016 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.06.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.06.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.06.2025.ISIN NameCA45580J1012 INDIVA... ► Artikel lesen | |
| CSPC PHARMA | 0,791 | -1,84 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - NEW INDICATION FOR DUOENYI (IRINOTECAN HYDROCHLORIDE LIPOSOME INJECTION) OBTAINS MARKETING APPROVAL | ||
| ORAMED PHARMACEUTICALS | 2,620 | -1,95 % | Oramed Pharmaceuticals Inc.: Oramed Reports Fiscal Third Quarter 2025 Financial Results | Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million
NEW YORK, Nov. 17, 2025 /PRNewswire/ --... ► Artikel lesen | |
| ADASTRA | 0,120 | 0,00 % | Adastra Holdings Ltd.: Adastra Holdings Announces Completion of Sale of Subsidiaries | Langley, British Columbia--(Newsfile Corp. - October 15, 2025) - Adastra Holdings Ltd. (CSE: XTRX) (FSE: D2E0) (the "Company") announces that it has completed the sale of all of the issued and outstanding... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,940 | +3,30 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification | - Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 22,830 | +0,04 % | Acadia Pharmaceuticals stock price target raised to $37 by H.C. Wainwright | ||
| CATALYST PHARMACEUTICALS | 20,600 | 0,00 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 467,10 | -1,14 % | MADRIGAL PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| METRIOPHARM | - | - | MetrioPharm gains orphan drug status from EMA for MP1032 | ||
| MOLECULE HOLDINGS | 0,001 | 0,00 % | Molecule Holdings Inc. Provides Corporate Update | ||
| NUMINUS WELLNESS | 0,027 | -100,00 % | Numinus Wellness Inc.: Numinus Wellness Provides Corporate Update | Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative... ► Artikel lesen | |
| BAYER | 35,055 | -2,62 % | Jetzt diese Aktien kaufen?! Bayer, Gerresheimer, WashTec! | Bayer gehört sicher zu den positiven Überraschungen 2025 am deutschen Aktienmarkt. Operativ läuft es für die Leverkusener insbesondere im Pharmabereich rund. Und im kommenden Jahr könnte auch das Glyphosat-Desaster... ► Artikel lesen |
RESPIRERX PHARMACEUTICALS INC gehört der Branche Pharma an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RESPIRERX PHARMACEUTICALS INC finden Sie auf Wallstreet Online.